Skip to content
Politically.com Search all
Menu

Final rule 2026-12443

Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples

The Food and Drug Administration (FDA) is classifying the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2026-12443
Published
Jun 22, 2026
Effective
Jun 22, 2026
Comments close
Not supplied
Federal Register citation
91 FR 36976

Docket identifiers

  • Docket No. FDA-2026-N-6239

CFR references

  • Title 21, part 866